Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Compass Therapeutics, Inc. Common Stock

CMPX

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Last trade $0.5957
Day change -$0.0658 (-9.95%)
Day range $0.571 – $0.696
Volume 2,135,918
Market cap $119M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$118.86M
Price / earnings
—
Price / book
0.83×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.82×

Profitability

Earnings per share
-$0.48
Return on assets
-49.49%
Return on equity
-60.57%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
6.79×
Quick ratio
6.79×
Cash ratio
1.7×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$61.94M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CMPX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$6.76M$7.4M$6.91M$4.32M$2.99M$4.65M$4.91M$3.54M
Research and development$22.04M$19.58M$13.39M$13.67M$12.83M$16.42M$13.05M$13.04M
Total operating expenses$28.8M$26.98M$20.3M$17.99M$15.82M$21.07M$17.97M$16.57M
Operating income-$28.8M-$26.98M-$20.3M-$17.99M-$15.82M-$21.07M-$17.97M-$16.57M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$27.17M-$25.15M-$18.32M-$15.72M-$14.26M-$19.88M-$16.63M-$15.03M
Income taxes$0$0$0$0$0$0$0$0
Net income-$27.17M-$25.15M-$18.32M-$15.72M-$14.26M-$19.88M-$16.63M-$15.03M
Net income attributable to common shareholders-$27.17M-$25.15M-$18.32M-$15.72M-$14.26M-$19.88M-$16.63M-$15.03M
EBITDA-$28.77M-$26.96M-$20.28M-$17.97M-$15.8M-$20.97M-$17.83M-$16.43M
Basic earnings per share-$0.15-$0.13-$0.10-$0.08-$0.08-$0.14-$0.12-$0.11
Diluted earnings per share-$0.15-$0.13-$0.10-$0.08-$0.08-$0.14-$0.12-$0.11

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

Compass Therapeutics announced positive Phase 2/3 COMPANION-002 results for tovecimig in combination with paclitaxel for previously treated advanced biliary tract cancer, meeting primary endpoint of ORR (18.0% vs 5.3%) and key secondary endpoint of PFS with 56% reduction in disease progression risk. However, the intent-to-treat OS analysis showed no statistically significant difference due to high crossover rates (85% of patients ultimately received tovecimig). Safety profile was consistent with prior studies and the anti-VEGF class.

GlobeNewswire Inc.

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

Compass Therapeutics announced that its abstract for tovecimig, a DLL4 x VEGF-A bispecific antibody, has been accepted for an oral presentation at the ESMO Congress 2026 in Madrid. The presentation will showcase Phase 2/3 COMPANION-002 trial results evaluating tovecimig combined with paclitaxel in patients with advanced biliary tract cancer, to be presented by Dr. Nilofer Azad from Johns Hopkins University on October 24, 2026.

GlobeNewswire Inc.

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

Compass Therapeutics announced Phase 1 clinical data for CTX-8371, a novel PD-1×PD-L1 bispecific antibody, showing promising monotherapy activity in patients with advanced malignancies resistant to prior checkpoint inhibitors. The drug demonstrated deep and durable responses in triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer, with a 33% overall response rate at the highest dose levels and no dose-limiting toxicities observed.

GlobeNewswire Inc.

Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Johnson Fistel, PLLP is investigating potential securities law violations by Compass Therapeutics following the disclosure that its lead drug candidate tovecimig failed to meet the overall survival secondary endpoint in the COMPANION-002 clinical trial. The company reported median overall survival of 8.9 months versus 9.4 months for the control arm, resulting in significant stock price decline. Investors who suffered losses are encouraged to contact the firm.

GlobeNewswire Inc.

Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

Compass Therapeutics will host a webcast on April 27, 2026 to present topline secondary endpoints from its Phase 2/3 COMPANION-002 study evaluating tovecimig, a DLL4 x VEGF-A bispecific antibody combined with paclitaxel, in patients with advanced biliary tract cancer. The study has reached its prespecified event threshold of 80% overall survival events.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.